Navigation Links
Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit
Date:4/6/2011

MIAMI, April 6, 2011 /PRNewswire/ -- Fuisz Pharma LLC announced today a new generation of solid dosage form designs that facilitate swallowing and esophageal transit.

Clinical studies demonstrate that these new designs and principles thereof speed esophageal transit by 80%, ease the swallowing experience, and reduce the incidence of esophageal transit failure, as compared with the conventional tablet designs currently used.

Joseph Fuisz, managing partner of Fuisz Pharma stated: "We stand at a crossroads where there is a keen understanding of the importance of compliance and the challenges to compliance posed by an aging population throughout the developed world.  At the same time however, cost containment pressures -- manifested primarily in reimbursement schemes -- make it challenging for branded pharma to broadly adopt value added drug delivery technologies."

"Our intention with this effort was to take existing tablet granulations and approach the question of form – as it relates to swallowability – from first principles.  The results were quite astonishing in that we demonstrated the ability to make enormous improvements in the swallowability of conventionally manufactured dosage forms.  Literally, we are able to take the existing granulation and stamp out a dramatically better performing product.  This advance also applies to capsules.  We are pursuing new dosage form classification for these next generation shapes in order to properly recognize their therapeutic value and to maximize the life cycle management benefit to our partners."

Richard C. Fuisz, M.D., a founder of Fuisz Pharma, commented: "I have had the privilege of making substantial contributions to the development and commercialization of orally dissolving tablets and orally soluble films, both of which were granted new dosage form classification to distinguish them from the then existing dosage forms.  Our new solid dosage form designs will represent my third oral dosage form and will ultimately prove to be the most important due to their extraordinary combination of high performance and ease of manufacture."

The breakthrough is backed by clinical studies as well as in vitro studies and will change the way tablets and capsules look in the future. The work includes the end product as well as the press and mold designs to produce them. The inventions have been filed with the Unite States Patent and Trademark Office through multiple filings .

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami.  www.fuisz.com.


'/>"/>
SOURCE Fuisz Pharma LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Pharma Releases Clinical Photos of Its Opioid Abuse Detection System
2. Fuisz Announces Issuance of Patent for the New Generation of Glucose and Other Analyte Analyzers
3. Fuisz Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform
4. FUISZ Announces Advances in Devices and Solid Dosage Form
5. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
6. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
7. Harnessing Patients Good Intentions Can Cut 33% of Americas Pharmacy-Related Waste
8. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
9. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
10. ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle
11. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... May 31, 2016  Diplomat Pharmacy, Inc. (NYSE: ... that Phil Hagerman , Chairman & CEO, and ... Blair 36 th Annual Growth Stock Conference in ... Mr. Whelan are scheduled to present at the conference on ... live audio-only webcast of the presentation and related presentation materials ...
(Date:5/31/2016)... , May 31, 2016 ... and Annotate Content From Elsevier,s ScienceDirect Database ... scientific, technical and medical information products and services, ... Berlin -based scientific collaboration platform PaperHive to enable ... over 12 million articles on ScienceDirect , ...
(Date:5/31/2016)... PUNE, India , May 31, 2016 ... 2016" market research report with comparative analysis of Asthma ... mechanism of action (MoA), route of administration (RoA) and ... and press releases. It also reviews key players involved ... on late-stage and discontinued projects. Complete report ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... CallTrackingMetrics's software gives ... monitor the performance of sales and support staff, and to efficiently route calls ... allows customers to record, transcribe, route, document, and report on everything going on ...
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international leaders ... spa and beauty in Europe. The organization asked its partner experts in Europe - ... - to forecast where wellness is headed in Europe. Predictions range from European nations ...
(Date:5/31/2016)... ... 2016 , ... Interest is on the rise for using the CRISPR-Cas9 system ... for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with a ... RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens have ...
(Date:5/31/2016)... ... ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree from ... where he graduated in the top ten percentile of his class. Dr. Ditta has ... has been a member in good standing for thirty years in the American Dental ...
(Date:5/30/2016)... (PRWEB) , ... May 30, 2016 , ... As the ... for their children and their efforts to keep their households lice free. , ... Hawaii are enacting new policies that keep kids in the classroom despite the fact ...
Breaking Medicine News(10 mins):